← Eichor
Study identifier: NCT03708224 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Condition: Cancer · Carcinoma · Squamous Cell Carcinoma  ·  Sponsor: Alain Algazi

PhasePhase 2
Planned participants55
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

UCSF HDFCCC Cancer Immunotherapy Program (CIP)  ·  (877) 827-3222  ·  HDFCCC.CIP@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of San Francisco, CaliforniaSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03708224